Trombosis
TT 103MH

[ Cerrar ]

thrombotarget

 

 thrombotargets

   
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
       

  
 

Antihemorrhagic information


Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders. 



Antihemorrhagic

We are developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. The most advanced drug candidate, TT-103MH, is a proprietary targeted antihemorrhagic human recombinant protein that induces a fast, efficient and stable blood coagulation.

Procoagulant factors

Biotechnology's innovation. Latest discover of recombinant human protein with procoagulant factors to stop bleeding, topically. The TT-103MH is being developed by Thrombotargets and will arrive at clinical phase at beginning of 2008.

Haemostatic drug

Know the novel TT-103MH, the haemostatic drug by Thrombotargets. It is a new way for treating topically all kinds of bleeding. See here the characteristics of this revolutionary haemostatic drug.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:


BioPlatformScreen
Antihemorrhagic
Therapeutics
Product candidates
Other services
© 2006 - Thrombotargets Corp. All rights reserved - coagulation - treatment